Impact of molecular diagnostics and targeted cancer therapy on patient outcomes (MODIFY): a retrospective study of the implementation of precision oncology
MODIFY is a retrospective study of 94 CHL oncology department patients who underwent comprehensive gene panel sequencing (313 genes) of their tumors for potential targeted treatments.
Why did we undertake this study?
Advanced solid tumours remain a therapeutic challenge. New oncological therapies try to increase the survival and quality of life in these patients. One of these new treatment options is targeted therapy based on a genetic analysis of tumour tissue. We wanted to evaluate this approach.
What is the specific question(s) we wanted to answer?
To analyse if targeted therapy based on a comprehensive genetic analysis of solid tumors was effective to increase the progression free survival rate.
What did we find?
54% of the 94 oncological patients in whom the gene analysis was performed, had targetable mutation. 11 Patients received a targeted therapy, of whom 62.5% had a 1.3-fold longer progression free survival time compared to their response under previous standard therapy.
What are the implications of our findings?
Targeted therapy based on genetic analysis of tumor tissue improves the clinical outcome. Studies with larger cohorts should be undertaken to evaluate individual mutational targets to further improve precision therapy decision-making.
Authors :
- Michaël Dang
- Anna Schritz
- Nikolai Goncharenko
- Guy Berchem
More information
If you also want to start a research project at the CHL, please contact our Research Department.